Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Retraction: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2019 Apr 15;79(8):2085. doi: 10.1158/0008-5472.CAN-19-0560. No abstract available.

PMID:
30987981
2.

Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.

Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V.

J Cell Sci. 2012 Nov 15;125(Pt 22):5578-86. doi: 10.1242/jcs.106815. Epub 2012 Aug 16.

3.

ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.

Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G.

OMICS. 2011 May;15(5):305-12. doi: 10.1089/omi.2010.0084. Epub 2011 Feb 19.

PMID:
21332394
4.

Unleash the wild type: restoration of p53 suppressive activity in skin cancer.

Madar S, Stambolsky P, Rotter V.

Cell Cycle. 2011 Mar 1;10(5):736-7. Epub 2011 Mar 1. No abstract available.

PMID:
21311232
5.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94. Epub 2010 Aug 6.

6.

Modulation of the vitamin D3 response by cancer-associated mutant p53.

Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V.

Cancer Cell. 2010 Mar 16;17(3):273-85. doi: 10.1016/j.ccr.2009.11.025. Erratum in: Cancer Cell. 2010 May 18;17(5):523. Sigfried, Zahava [corrected to Siegfried, Zehava].

7.

The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity.

Zemach A, Paul LK, Stambolsky P, Efroni I, Rotter V, Grafi G.

Exp Cell Res. 2009 Dec 10;315(20):3554-62. doi: 10.1016/j.yexcr.2009.07.022. Epub 2009 Aug 6.

PMID:
19647732
8.

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V.

Mol Cell Biol. 2007 Dec;27(23):8228-42. Epub 2007 Sep 17.

9.

Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.

Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N, Rotter V.

Cancer Res. 2006 Nov 15;66(22):10750-9.

10.

Regulation of AIF expression by p53.

Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V.

Cell Death Differ. 2006 Dec;13(12):2140-9. Epub 2006 May 26.

11.

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.

Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M.

Oncogene. 2006 Jan 19;25(3):359-69.

PMID:
16170349
12.

Transactivation of the EGR1 gene contributes to mutant p53 gain of function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2004 Nov 15;64(22):8318-27. Retraction in: Cancer Res. 2019 Apr 15;79(8):2085.

13.

p53-dependent down-regulation of telomerase is mediated by p21waf1.

Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V.

J Biol Chem. 2004 Dec 3;279(49):50976-85. Epub 2004 Sep 15.

14.

Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter.

Erez N, Stambolsky P, Shats I, Milyavsky M, Kachko T, Rotter V.

FEBS Lett. 2004 Jun 4;567(2-3):311-5.

15.

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.

Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M.

Oncogene. 2003 Aug 28;22(36):5667-76.

PMID:
12944915
16.

Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V.

EMBO J. 2001 Aug 1;20(15):4163-72.

17.

The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop.

Almog N, Milyavsky M, Stambolsky P, Falcovitz A, Goldfinger N, Rotter V.

Carcinogenesis. 2001 May;22(5):779-85.

PMID:
11323398

Supplemental Content

Loading ...
Support Center